Abbott i-STAT 1 System Manual page 500

References
1. Braunwald, E, et al. ACC/AHA 2002 guideline update for the management of patients with
unstable angina and non-ST-segment elevation myocardial infarction: a report of the American
College of Cardiology/American Heart Association Task Force on Practice Guidelines
(Committee on the Management of Patients with Unstable Angina). 2002. Available at: http://
content.onlinejacc.org/article.aspx?articleid=1130417.
2. Thygesen K, Alpert JS, White HD, et al. Universal definition of myocardial infarction. Circulation.
2007; 116:2634-2653.
3. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 Guidelines for the management of
patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American
College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing
Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/
Non-ST-Elevation Myocardial Infarction). Circulation. 2007;116:e148-e304.
4. Antman EM, Tanasijevic, MJ, Thompson B, et al. Cardiac-specific troponin I levels to predict the
risk of mortality in patients with acute coronary syndromes. NEJM 1996, 335(18): 1342-1349.
5. Galvani M, Ottani F, Ferrini D, et al. Prognostic influence of elevated values of cardiac troponin I
in patients with unstable angina. Circulation 1997, 95: 2053-2059.
6. Morrow DA, Rifai N, Tanasijevic MJ, et al. Clinical efficacy of three assays for cardiac troponin I
for risk stratification in acute coronary syndromes: A thrombolysis in myocardial infarction (TIMI)
IIB substudy. Clin Chem 2000, 46(4): 453-460.
7. Sabatine MS, Morrow DA, de Lemos JA, et al. Multimarker approach to risk stratification in non-
ST-elevation acute coronary syndromes: Simultaneous assessment of troponin I, C-reactive
protein, and B-type natriuretic peptide. Circulation 2002, 105: 1760-1763.
8. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative
strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa
inhibitor tirofiban. NEJM 2001, 344(25): 1879-1887.
9. Morrow DA, Antman EM, Tanasijevic MJ, et al. Cardiac troponin I for stratification of early
outcomes and the efficacy of enoxaprin in unstable angina: A TIMI-IIB substudy. JACC 2000, 36:
1812-1817.
10. Hamm CW, Heeschen C, Goldmann B, et al. Benefit of abciximab in patients with refractory
unstable angina in relation to serum troponin T levels (CAPTURE Study Investigators). NEJM
1999, 340: 1623-1629.
11. Babuin and Jaffe. Troponin: the biomarker of choice for the detection of cardiac injury. Can.
Med. Assoc. J. 2005; 173:1191.
12. Hickman et al. Cardiac troponin may be released by ischemia alone, without necrosis. Clin Chem
Acta 2010; 411: 318-323.
13. See "Troponin: What Laboratorians Should know to Manage Elevated Results" at http://www.
fda.gov/MedicalDevices/Safety/AlertsandNotices/TipsandArticlesonDeviceSafety/ucm109362.
htm.
14. Wu et al. NACB Standards of Laboratory Practice: Recommendations for the use of cardiac
markers in coronary artery disease. Clin. Chem. 1999; 45:1104.
15. CLSI. Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline –
Second Edition. CLSI document EP9-A2 [ISBN 1-56238-472-4]. CLSI, 940 West Valley Road,
Suite 1400, Wayne, Pennsylvania 19087-1898, USA 2002.
16. P.J. Cornbleet and N. Gochman, "Incorrect Least-Squares Regression Coefficients in Method-
Comparison Analysis," Clinical Chemistry 25:3, 432 (1979).
17. CLSI. Interference Testing in Clinical Chemistry; Approved Guideline. CLSI document EP7-A
[ISBN 1-56238-480-5]. CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-
1898, USA 2002.
18. Clinical and Laboratory Standards Institute (CLSI) Immunoassay Interference by Endogenous
Antibodies; Proposed Guideline. CLSI document I/LA30-P (ISBN 1-56238-633-6) Clinical and
Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-
cTnI - 8
Art: 715595-01R Rev. Date: 01-Jul-13